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In this study, the potential antileukemic activity of grandisin, a lignan extracted from Piper solmsianum, 
was evaluated against the leukemic line K562. The cytotoxicity of grandisin (0.018 to 2.365 µM) was 
evaluated in K562 and normal peripheral blood lymphocytes by Trypan Blue Exclusion and MTT methods 
after 48h exposure to the drug. In both methods, cellular viability was concentration-dependent and the 
IC50 values were lower than 0.85µM. Analysis of K562 cells after treatment with grandisin showed 
that the cell cycle was arrested in the G1 phase with a 12.31% increase, while both S and G2 phases 
decreased. Morphological studies conducted after the exposure of K562 to grandisin revealed changes 
consistent with the apoptosis process, which was confirmed by anexin V stain and caspase activation. 
Thus, lignan grandisin showed antileukemic activities against the K562 cell line and the cell death 
process occurred via apoptosis.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal 
myeloproliferative syndrome characterized by the 
presence of the Philadelphia chromosome - Ph (Faderl et 
al., 1999). The Ph chromosome contains the chimeric gene 
BCR-ABL, which produces a tyrosine kinase. Uncontrolled 
BCR-ABL tyrosine kinase activity is a conditio sine qua 
non for the protein´s skill to transform cells (Eiring et 
al., 2011). The expression of BCR-ABL also contributes 
to apoptosis resistance after the withdrawal of growth 
factors, oxidative stress and DNA damage. The ability to 
escape normal cell death programs provides a remarkable 
proliferative advantage for tumoral cells, especially 
during the accelerated or blast phase of the disease and 
hinders successful treatment since it is well-known that 
CML cells are highly resistant to apoptosis induced by 
chemotherapeutic drugs (Ren, 2005; Fernandez-Luna, 
2000; O’Hare et al., 2012; Jabbour, Kantarjian, 2014).
Apoptosis, a type of programmed cell death which 
occurs in physiological and pathological conditions, 
is a prime target in designing therapeutic strategies to 
induce cancer cell death. This process shows typical 
cellular morphologic changes such as rounding-up of 
the cell, chromatin condensation, nuclear fragmentation, 
plasma membrane blebbing and engulfment by resident 
phagocytes (in vivo) (Ziegler et al., 2004; Kroemer et al., 
2009). Moreover, many coordinated pathways with a wide 
range of proteins and enzymes are involved in this process. 
Caspase activation and translocation of phosphatidylserine 
from the inner leaflet of the cytoplasmic membrane to the 
outer leaflet are common events which occur in apoptotic 
cells. In addition, the Bcl-2 protein family plays a pivotal 
role in the regulation of apoptosis (Wong, 2011; Fleischer 
et al., 2006).
Currently, the most promising treatment for CML is 
TKI (tyrosine kinase inhibitors)-based therapy (O’Hare et 
al., 2012). The gold standard of care in CML is imatinib 
mesylate which inhibits BCR-ABL activities and induces 
apoptosis in tumoral cells. In recent years, however, a 
second and third generation of TKIs have been introduced 
in therapeutics especially due to imatinib drug resistance 
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and toxicity. Despite the benefits of TKI therapy, the 
persistence of minimal residual disease (MRD) and 
the presence of active disease even with BCR-ABL1 
inhibition, the development of new target drugs against 
CML is necessary (O’Hare et al., 2012; Piccaluga et 
al., 2012). In this context, natural compounds have 
been investigated as potential sources for new chemical 
entities and in order to develop drugs against various 
pharmacological targets, including leukemias (De Martino 
et al., 2011).
The tetrahydrofuran lignan grandisin, isolated 
from Virola and Piper species, presents antimalarial and 
trypanocidal activities, as well as having antitumoral 
properties. Furthermore, grandisin CYP450-mediated 
biotransformation obeys Michaelis–Menten kinetics 
and its metabolism results in the formation of four 
demethylated metabolites (Zhang et al., 2001; Valadares 
et al., 2009; Barth et al., 2015). Grandisin antitumor 
properties were investigated by our group both in in vitro 
and in vivo assays using the Ehrlich Ascites Tumoral (EAT) 
model. The treatment of EAT-bearing mice with grandisin 
(2.5, 5.0 or 10.0 mg/kg) for 10 days, significantly increased 
the survival of the animals, in a dose-dependent manner. 
At the same time, a 66% reduction in intraperitoneum 
tumor cell burden in the animals treated with 10mg/kg 
of grandisin was observed. Furthermore, the marked 
increase in vascular endothelial growth factor (VEGF) 
levels induced by EAT development in these animals was 
also significantly reduced after treatment with grandisin, 
and resulted in a 32% reduction of VEGF levels, when 
compared to the control. Finally, caspase activation 
(caspase-3, -6, -8 and -9) was detected after EAT cells were 
exposed to grandisin (Valadares et al., 2009). On-going 
studies performed by our group demonstrated that this 
lignan has a protective effect against cyclophosphamide-
induced mutagenicity and this effect could be associated 
to grandisin bioactivation (Valadares et al., 2011).
In the light of this, the present study was designed to 
explore the potential antileukemic properties of grandisin 
on K562 cells (a human erythroleukemia cell line) and 
normal lymphocytes. Furthermore, the effects of this 
potential drug on the cell cycle and death mechanism were 
also investigated by flow cytometry with caspase activation.
MATERIAL AND METHODS
Grandisin
Grandisin was isolated from the extract obtained 
from the leaves of Piper solmsianumas previously 
described (Martins et al., 2003).
Grandisin nanoemulsion
Grandisin was prepared as a nanoemulsion disperse 
system in order to obtain a formulation with an aqueous 
external phase as previously described (Valadares et al., 
2009).
Briefly, the dispersion was prepared as follows: 
first, a mixture of 50 µg of soy phosphatidylcholine 
(PC), sunflower oil (4:1 mol/mol PC), and grandisin (10 
mg/mL) were dissolved in 1.0 mL of chloroform. The 
mixture was dried under a nitrogen atmosphere and kept 
under vacuum overnight to ensure the complete removal 
of chloroform. Then 1 mL of water was added to the 
dried lipid film to promote the hydration of the lipid-drug 
mixture, which after a 2 min vortex mixing, resulted in 
a coarse O/W emulsion. After 1 hour, the mixture was 
sonicated for 10 min in a Titanium probe sonicator to 
obtain a homogeneous submicrometric emulsion. For the 
control group, the nanoemulsion was prepared without 
adding grandisin to the oil phase.
Cell lines and culture
K562 erythroleukemia cell line, obtained from the 
American Type Culture Collection (ATCC, Rockville, MD, 
USA), was cultured in suspensions in RPMI 1640 medium 
(Sigma Chemical Co.) supplemented with 10% fetal calf 
serum (FCS, Sigma Chemical Co.), 100 U/mL of penicillin, 
and 100 ug/mL of streptomycin in a humidified atmosphere 
at 37 °C in 5% CO2. Cells were seeded (1 x 106 cells/mL) 
in 96-well microtiter plates and incubated with different 
concentrations of grandisin for 48 hours (Queiroz et al., 
2009). The human blood used in the assays was collected 
from healthy volunteers who had signed a consent form.
Lymphocyte culture
Peripheral human blood, obtained by venipuncture 
from healthy adult donors, was diluted with an equal 
volume of RPMI 1640 medium, then layered over 
Ficoll-Hypaque density gradient separation solution 
(1.077g/mL), and centrifuged at 400g for 20 min at room 
temperature. The mononuclear cell layer was removed, 
washed twice in RPMI 1640 medium and resuspended in 
RPMI 1640 medium supplemented with 2 mM glutamine 
(Sigma Chemical Co.), antibiotics and 10% FCS. The cells 
were then cultured with 10 µg/mL of phytohemagglutinin. 
Lymphocytes at a density of 1 x 106 cells/mL were seeded 
in 96-well microtiter plates, in the presence and absence 
of grandisin, for 48 hours in a humidified atmosphere at 
37 °C in 5% CO2 (Queiroz et al., 2009).
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Cell proliferation and viability assays
Cel l  prol i fera t ion was  determined by the 
3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenytetrazolium 
bromide (MTT, Sigma Chemical Co.) reduction test, 
performed as previously described by Mosmann 
(1983). Briefly, 1 x 106 cells/mL in RPMI 1640 medium 
supplemented with 10% FBS were seeded in a 96-well, 
flat-bottom plate (TPP, Trasadingin, Swiss) and treated 
with different concentrations of grandisin (0.018 – 2.365 
µM) for 48 hours. After incubation, 10µL/well MTT 
(5mg/mL) were added and the plate was incubated 
again for 4 hours. It was then centrifuged at 800 rpm 
for 10 min and the supernatant removed. A total of 100 
µL of dimethylsulphoxide (DMSO) was added to each 
well to solubilize the formazan crystals. Absorbance 
was measured at 545nm using a spectrophotometer 
(Stat Fax 2100, Awareness Technology, Dusseldorf, 
Germany). 
Trypan blue dye exclusion assay was used to assess 
cell viability as previously described (Bromberg et al., 
2005). The cells were seeded in a 96-well, flat-bottom 
plate (TPP, Trasadingin, Swiss), at 1 x 106 cells/mL in 
RPMI 1640 medium supplemented with 10% FBS and 
treated with different concentrations of grandisin (0.018 – 
2.365 µM) for 48 hours. An aliquot of the cell suspension 
was then mixed with trypan blue solution (0.2% in 
phosphate-buffered saline-PBS) (1:10) and the viability 
of the cells was estimated using a hemocytometer 
(Reichert, USA). Cells which incorporated the dye and 
turned blue were reported as dead. Each concentration 
was tested in three independent experiments run in four 
replicates. Proliferation and viability of cells exposed 
to grandisin were expressed as a percentage of the 
cell proliferation or viability of untreated control cells 
(100%).
Methods for detection of cell death by apoptosis
Apoptotic index
K562 cells were incubated in a humid chamber at 
37 °C, 5% CO2, with grandisin 0.036 µM for 24 h. After 
this period, cells were stained with hematoxylin and 
analysed at 40X magnification. The number of apoptotic 
cells was expressed as a percentage of the total number 
of cells. The Apoptotic index was determined after a 
minimum of 100 cells were counted. Cells showing 
morphological characteristics of apoptosis such as 
marginalization or chromatin condensation, cellular or 
nuclear fragmentation, and cellular structures fragmented 
into vesicles (apoptotic bodies) were considered positive.
Annexin V-FITC/PI double-staining and analysis 
by flow cytometry
After incubation with grandisin as described 
above, K562 cells were harvested, washed with cold 
PBS and resuspended in binding buffer at a concentration 
of 1 x 106 cells/mL,according to the manufacturer’s 
instructions(eBioscience, USA). The suspensions were 
transferred to 5 mL tubes, and 5 µL Annexin V-FITC and 
5 µg/mL PI were added. The cells were incubated at room 
temperature for 20 min, after which 300 µL binding buffer 
were added and analysis was performed in a FACSCantoII 
flow cytometer using the CellQuest software (10.000 
events were collected per sample). Control cells were 
treated with medium only.
Cell cycle
For analysis of the cell cycle, 5 x 105 cells were 
incubated with or without grandisin 0.036 µM for 24 h 
in RPMI 1640 medium and 10% fetal calf serum, in an 
incubator with 5% CO2 at 37 °C. After that, the cells were 
washed twice with 1 mL of cold PBS, and centrifuged at 
1500 rpm for 10 min. The cell button was resuspended 
with 1 mL of fixative solution (previously prepared 70% 
ethanol) and incubated at 4 °C overnight. Cells were 
then washed in cold PBS and resuspended in 1 mL of 
200 μg/mL RNAse A and 50 μg/mL propidium iodide, 
and maintained at 4 °C, protected from the light, for 2 h. 
Samples were analyzed by flow cytometry (FACSCanto 
II, Becton Dickinson). Results were presented in graphs 
representing the number of cells versus DNA content 
indicated by fluorescence intensity.
Caspase activity
Direct measurements of caspase activity were 
performed using colorimetric protease kits (R&D Systems, 
USA), according to the manufacturer’s recommendations, 
after the incubation of cells with grandisin(0.036 μM/
mL) for 24 h. The caspase activity assay is based on 
the spectrophotometric detection of the p-nitroanilide 
(pNA) chromophore after cleavage from the substrates 
X-pNA, where X stands for amino acid sequences 
recognized by specific caspase-6 (VEIDI-pNA), caspase-8 
(IETD-pNA) and caspase-9 (LEHD-pNA). According 
to the procedure, 2 x 106 K562 cells were pelleted by 
centrifugation and lysed on ice. The protein concentration 
in the lysate was measured using a Bio-Rad Protein assay 
(Bio-Rad Laboratories Inc., USA). This assay is based 
on the Bradford method in which 200 μg of protein 
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were incubated with each X-pNA substrate (200 μM 
final concentration) at 37 °C in a microtiter plate. The 
optical density of samples was measured at 405nm. After 
subtraction of the blank, the increase in caspase activity 
was determined by comparing these results with the levels 
of the control.
Statistics
Cytotoxicity evaluation was performed in three 
independent experiments. Results were converted 
into percentage of control. IC50 (concentration 
which produces an inhibitory effect of 50% of the 
evaluated parameter) was obtained graphically from the 
concentration-response curve. Results were expressed 
as mean ± S.D. of four replicates. For the parameters 
‘apoptotic index’ and ‘caspase activity’, statistical 
analysis was performed using the nonparametric Mann-
Whitney test to compare the treated groups with controls 
and the Kruskal-Wallis test to compare the treated groups 
with each other. Statistical significance was considered 
when p <0.05.
RESULTS AND DISCUSSION
Effects of grandisin on cell proliferation and 
viability of K562 cells and normal lymphocytes.
The effect of grandisin on the growth and viability 
of K562 cells and lymphocytes was examined, using 
the Trypan blue exclusion method, after 48 hours of 
exposure in culture. The proliferation of K562 cells and 
lymphocytes was inhibited in a concentration-dependent 
manner in response to increased concentrations of 
grandisin (0.018 to 2.365 µM) (Figure 1a). The 50% 
inhibition (IC50) was obtained with a concentration of 
0.851 µM for K562 and 0.685 µM for lymphocytes after 
48 hours of exposure (Figure 1a). On the other hand, 
results obtained by the MTT method showed that the 50% 
inhibition (IC50) values were 0.198 µM for K562 and 
0.200 µM for lymphocytes (Figure 1b). 
Thus, our data demonstrated that grandisin was 
more cytotoxic for lymphocytes than for K562 cells 
in the Trypan blue assay. However, in the MTT assay 
the cytotoxicity of grandisin was quite similar for both 
types of cells. Although grandisin proved to be cytotoxic 
to K562 cells, it was also toxic for lymphocytes in the 
same range of concentrations tested. These results 
are important because they demonstrate that even 
though grandisin exerts anti-leukemic activity, it may 
act similarly to many other chemotherapeutic agents 
exhibiting toxicity to normal cells and triggering 
undesirable side effects, which thus limits its application 
in the clinical field (Bhatt, Saleem, 2004). However, the 
lymphotoxicity of grandisin opens up new treatment 
fields, such as the immunosuppressive agent similar to 
PKC412 (CGP41251), a protein kinase inhibitor which 
has antitumoral and immunosuppressive activities 
(Ganeshaguru et al., 2002; Miyatake et al., 2007; 
Kawamoto et al., 2008).
Cell cycle analysis by flow cytometry
Results from the experiments designed to evaluate 
whether grandisin interferes with the cell cycle showed 
that it caused a significant G1 phase arrest with an increase 
of 12.31% in the population of cells and a decrease of 
12.06% and 0.25% in the population of cells in the S and 
G2 phases, respectively, when compared with the control 
(Figures 2a and 2b).
FIGURE 1 - Cytotoxicity in K562 cells and normal peripheral blood lymphocytes (1 x 106 cells/mL) treated with different 
concentrations of grandisin (0.018 – 2.365 µM) for 48 hours. (a) Cell viability was determined by the Trypan blue exclusion method. 
(b) Cell proliferation was assessed by the MTT reduction test. In the absence of compound, the viability was considered as 100%. 
Results represent the mean ± SD of three experiments run in four replicates (p< 0.05 compared with control cells).
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This analysis demonstrated that there was an 
increase in G1 population and a decline in cell population 
in the S and G2 phases which indicates that grandisin can 
interfere with cellular proliferation and with the dynamics 
of the cell cycle.
Apoptosis induction by grandisin in K562 cells
Apoptosis index
Once the ability of grandisin to induce the death 
of leukemic cells was detected, we studied the sequence 
of mechanisms involved in cell death, especially the 
apoptotic mechanisms. To understand the mechanism 
by which grandisin promotes loss of viability in K562 
cells, a number of apoptosis related experiments were 
performed. The effects of grandisin on the morphology 
of K562 cells were examined after 24 hours of exposure 
in culture (Figures 3a and b). Results showed a 4-fold 
increase in the number of cells undergoing apoptosis 
when compared to the control. As indicated in the 
photomicrographs, the cells showed morphological 
characteristics of death by apoptosis such as condensed 
chromatin, vacuoles, and fragmentation of the DNA and 
of the cellular membrane. A 40% increase in the number 
FIGURE 2 - (a) Analysis of the cell cycle of K562 cells (control) by Flow Cytometry. (b) Analysis of the cell cycle of K562 cells 
after treatment with grandisin 0.036 µM for 24 hours.
FIGURE 3 - (a) Apoptosis rate of K562 cells exposed to grandisin 0.036 µM for 24 hours. The rate of apoptosis was determined 
by counting 100 cells, each sample was duplicated and the number of apoptotic cells was expressed as a percentage of the total 
number of cells. (b) (2, 3 and 4) Morphological characteristics of apoptosis induced K562 cells treated with grandisin 0.036 µM for 
24 hours, determined by hematoxylin coloration. Arrows indicate vacuoles, membrane fragmentation and condensed chromatin, 
respectively. (b) (1) Morphological characteristics of untreated cells.
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of cells undergoing apoptosis was also observed when 
compared with the control.
Annexin V-FITC/PI double-staining and analysis 
by flow cytometry
Once the antitumoral properties of grandisin were 
determined, we focused on the mechanisms involved in 
this process. Since morphological changes in K562 after 
treatment pointed to death by apoptosis, flow cytometry 
analysis with Annexin V/PI stain was conducted. 
The exposure to grandisin was performed in three 
concentrations (0.018, 0.036 and 0.072 µM) for 24 hours 
(Figure 4). In the concentration of 0.018 µM, the increase 
in cells in early and late apoptosis was 11.42% and 
8.22%, respectively. In the intermediate concentration 
(0.036 µM), the percentage of cells in early apoptosis 
was 39.77% and 39.90% in late apoptosis. Finally, in 
0.072 µM the increase in early and late apoptosis was 
23.26% and 46.52%, respectively. The results confirmed 
that the death mechanism triggered by grandisin was 
apoptosis.
Caspase activity
A molecular hallmark of apoptosis is the activation of 
caspases – specific proteases which bring about cell death 
through cleavage of multiple protein substrates such as 
nuclear and cytoskeletal proteins (Bao; Shi, 2007; Elmore, 
2007). In this context, caspase-6, -8 and-9 activities were 
analyzed by colorimetric assays. All caspases analyzed 
showed increases in activities of 21.4%, 29% and 37% for 
caspases-6, -8 and -9, respectively (Figure 5).
Our results showed an increase in all caspase 
activities tested after exposure of K562 to grandisin 
which suggests that intrinsic and extrinsic cascades were 
activated. Similar results were observed with apigenin in 
human breast cancer cells and with emodin in HeLa cells 
(Choi, Kim, 2009; Yaoxian et al., 2013).
Despite the many advances in cancer research, 
most antitumor compounds produce undesirable side 
effects. Thus, significant effort has been invested in 
finding new phytochemicals with antitumoral properties. 
Throughout history, natural compounds have been used 
for the treatment of cancer due to their safety, low toxicity, 
FIGURE 4 - Analysis of K562 cells treated with grandisin(1 x 106 cells/mL) for 24 hours. The cells were stained with Annexin 
V-FITC and propidium iodide. Dot plot of untreated (a) and treated (b, c and d). (b) K562 cells treated with 0.072 µM of grandisin. 
(c) K562 cells treated with 0.036 µM of grandisin. (d) K562 cells treated with 0.018 µM of grandisin.
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and availability from natural sources (Pratheeshkumar 
et al., 2012). Grandisin is a lignan extracted from Piper 
solmsianum which presents antitumoral properties as 
well as antimalarial and trypanocidal activities (Martins 
et al., 2003; Bernardes et al., 2006; Valadares et al., 
2011). Despite its lymphocytic activities, grandisin did 
not exert mutagenic effects on the bone marrow cells of 
exposed mice. Moreover, grandisin proved to be a potent 
antiangiogenic compound due to the prolonged survival 
of mice bearing breast carcinoma (Valadares et al., 2011). 
Other pharmacological properties, such as antinociceptive, 
anti-inflamatory and antioxidant activities, have also 
been attributed to grandisin, which thereby shows the 
therapeutic versatility of this compound (Carvalho et al., 
2010). 
Thus, this study introduces a new agent capable 
of inducing apoptosis in a leukemic cell line which 
presents distinct features of resistance to many drugs. 
But it is important to highlight that further studies should 
be conducted to ensure the safety and efficacy of this 
substance and elucidate more clearly the mechanism 
which triggers apoptosis.
CONCLUSIONS 
The present study suggests that the lignin grandisin 
has antileukemic activities against the K562 cell line and 
that the cell death process occurs via apoptosis. Grandisin 
also showed immunosuppressant activities indicating new 
potential uses for immunological pathologies.
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